rc48-adc
Nasopharyngeal Carcinoma (NPC)
BeiGeneantibody_drug_conjugatePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Nasopharyngeal Carcinoma (NPC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pyrotinib BeiGene | Phase 1 | CC |
Bgb-A445 BeiGene | Phase 1 | CC |
Tislelizumab BeiGene | Phase 1 | CC |
Tabelecleucel | D |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →